期刊文献+

磷酸西格列汀联合地特胰岛素注射液治疗老年Ⅱ型糖尿病的效果 被引量:3

Effects of Sitagliptin phosphate combined with Insulin detemir injection on elderly patients with type 2 diabetes mellitus
下载PDF
导出
摘要 目的:观察磷酸西格列汀联合地特胰岛素注射液治疗老年Ⅱ型糖尿病(T2DM)的效果。方法:选取110例老年T2DM患者作为研究对象,按治疗方案的不同将其分为观察组和对照组各55例。对照组给予地特胰岛素注射液治疗,观察组在对照组的基础上给予磷酸西格列汀治疗。比较两组血糖达标情况、胰岛素使用剂量、治疗前后各项指标[糖化血红蛋白(HbAlc)、空腹血糖(FBG)、餐后2 h血糖(2 hPG)]水平、体质量[腰臀比(WHR)、体质量指数(BMI)]的变化情况及低血糖发生情况。结果:观察组血糖达标时间明显短于对照组,胰岛素使用剂量明显少于对照组,差异均有统计学意义(P<0.05);治疗后观察组HbAlc、2 hPG水平均明显低于对照组,差异有统计学意义(P<0.05);治疗后两组FBG水平比较,差异无统计学意义(P>0.05);治疗后观察组BMI、WHR明显低于对照组,差异有统计学意义(P<0.05);观察组低血糖发生率9.09%(5/55),明显低于对照组的32.73%(18/55),差异有统计学意义(P<0.05)。结论:磷酸西格列汀联合地特胰岛素注射液治疗老年Ⅱ型糖尿病的效果优于单纯地特胰岛素注射液治疗效果。 Objective: To observe effects of Sitagliptin phosphate combined with Insulin detemir injection on elderly patients with type 2 diabetes(T2 DM). Methods: 110 elderly patients with T2 DM were selected as the subjects, and they were divided into observation group(n=55) and control group(n=55) according to the different treatment options. The control group was treated with Insulin detemir injection, while the observation group was treated with Sitagliptin phosphate on the basis of that of the control group. The situations of the blood glucose level reaching the target value, the insulin dosage, and the indicator levels before and after the treatment [glycated hemoglobin(HbAlc), fasting blood glucose(FBG), postprandial 2 h blood glucose(2 hPG)], the changes of body mass [waist to hip ratio(WHR), body mass index(BMI)] and the occurrence of hypoglycemia were compared between the two groups. Results: The time of the blood glucose level reaching the target value of the observation group was significantly shorter than that of the control group;the insulin dosage was significantly lower than that of the control group;and the differences were statistically significant(P<0.05). The HbAlc and 2 hPG levels in the observation group were significantly lower than those in the control group after the treatment, and the differences were statistically significant(P<0.05). There was no statistical difference in the FBG level between the two groups after the treatment(P>0.05). After the treatment, the BMI and WHR of the observation group were significantly lower than those of the control group, and the differences were statistically significant(P<0.05). The incidence of hypoglycemia in the observation group was 9.09%(5/55), which was significantly lower than that in the control group(32.73%, 18/55), and the difference was statistically significant(P<0.05). Conclusions:Sitagliptin phosphate combined with Insulin detemir injection in the treatment of the elderly patients with T2 DM is superior to single Insulin detemir injection.
作者 丁艳 刘亚旭 DING Yan;LIU Yaxu(Department of Nephrology and Endocrinology of People’s Hospital of Xinzheng, Xinzheng 451100 Henan, China)
出处 《中国民康医学》 2019年第8期9-11,共3页 Medical Journal of Chinese People’s Health
关键词 老年 糖尿病 Ⅱ型 地特胰岛素注射液 磷酸西格列汀 The elderly Type 2 diabetes Insulin detemir injection Sitagliptin phosphate
  • 相关文献

参考文献7

二级参考文献43

  • 1杨文英.地特胰岛素治疗2型糖尿病的耐受性、安全性和依从性[J].中华糖尿病杂志,2009,1(1). 被引量:16
  • 2Herman G A, Bergman A, Stevens C, et al.Effectsin of single oraldoses sitagliptin, a dipeptidyl peptidase-4inhibitor, on ineretin andplasma glucose levels after an oral glucose tolerance test in patientswith type 2 diabetes[J].Clin Endocrinol Metab, 2006,91 ( 11 ):4612-4619.
  • 3Kim D , Wang L, Beconi M,et al. ( 2R ) -4-oxo-4-[3(trifluoromethyl) -5,6-dihydro[l, 2, 4]triazolo[4, 3-a]pyrazin-7(8H ) -yl]- (2,4,5-trifluorophenyl ) butan -2-amine:a pltent,orally acive dipeptidyl peptidase IV inhibitor for the treatment of type 2diabetes[J]J Med Chem, 2005, 48 (10):141-151.
  • 4Drucder D J, Nauck M A.GLP-1R agonists (incretin mimetics ) andDPP—4 inhibitors ( incretin enhancers ) for the treatment of tupe 2diabetds[J].Lancet, 2006, 368 (9):141-151.
  • 5Vilsboll T, Hoist J J.Incretins, insulin secretion and typdiabetes[J].Diabetologia, 2004, 47 ( 11 ):357-366.
  • 6Wang Q,Li L, Xu E, et al.Glucagon-like peptide-1 regulatesproliferation and apoptosis visa activation protein kinase B in pancreaticINS-1 beta [J].Diabetologia, 2004 , 47 ( 8 ) :478-487.
  • 7Stoffers D A.The development of beta-cell mass :recent progress andpeoliferation role of GLP-l[J].Horm Res, 2004, 36 ( 13 ) :811-821.
  • 8Raz I, Chen Y, WuM,et al.Efficacy and safety of sitagliptin addedto ongoing metformin therapy in patients with type 2 diabetes[J].CurrMed Res Opin, 2008 , 24 ( 2 ) :537-550.
  • 9Nonaka K, Kakikawa T, Sato A, et al.Efficacy and safety ofsitagliptin monotherapy in Japanese patients with type 2 diabetesfj].Diabetes Res Clin Pract, 2008, 79 ( 2 ) :291-298.
  • 10Hermansen K, Kipnes M, LuoE,etaLEfficacy and safety of Ae dipeptidylpeptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetesmellitus inadequately controlled on imepiride alone or on glimepiride andmetfonraii[J].Diabetes Obes Metab, 2007 , 9 ( 5):733-745.

共引文献6874

同被引文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部